Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials

Hassan, Mohamed
October 2014
Global Cardiology Science & Practice;2014, Vol. 2014 Issue 4, p179
Academic Journal
The article discusses the findings of the Myocardial Infarction Genetic Consortium and Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) randomized controlled trials which emphasize the clinical benefit of Niemann-Pick C1-Like 1 (NPC1L1) protein in the treatment of dyslipidemia. An overview of the IMPROVE-IT study, which aims to investigate the benefit from adding ezetimibe to simvastatin therapy in reducing cardiovascular (CV) events, is also given.


Related Articles

  • Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. Ha, Vanessa; Sievenpiper, John L.; de Souza, Russell J.; Jayalath, Viranda H.; Mirrahimi, Arash; Agarwal, Arnav; Chiavaroli, Laura; Blanco Mejia, Sonia; Sacks, Frank M.; Di Buono, Marco; Bernstein, Adam M.; Leiter, Lawrence A.; Kris-Etherton, Penny M.; Vuksan, Vladimir; Bazinet, Richard P.; Josse, Robert G.; Beyene, Joseph; Kendall, Cyril W. C.; Jenkins, David J. A. // CMAJ: Canadian Medical Association Journal;5/13/2014, Vol. 186 Issue 8, pE252 

    Background: Evidence from controlled trials encourages the intake of dietary pulses (beans, chickpeas, lentils and peas) as a method of improving dyslipidemia, but heart health guidelines have stopped short of ascribing specific benefits to this type of intervention or have graded the beneficial...

  • Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels. Berthold, Heiner K.; Seidah, Nabil G.; Benjannet, Suzanne; Gouni-Berthold, Ioanna // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate...

  • DYSLIPIDEMIA DRUG INDICATIONS.  // Monthly Prescribing Reference;Dec2013, Vol. 29 Issue 12, p25 

    A chart is presented which lists several dyslipidemia drugs along with their effects, brands and dosage forms including cholesterol absorption inhibitor ezetimibe, lipid regulating agent icosapent ethyl and bile acid sequestrant colesevelam.

  • Simultaneous Estimation of Rosuvastatin Calcium and Ezetimibe in Bulk and Tablet Dosage Form by Simultaneous Equation Method. Pandya, Chirag B.; Channabasavaraj, K. P.; Shridhara, H. S. // International Journal of ChemTech Research;Oct2010, Vol. 2 Issue 4, p2140 

    Rosuvastatin Calcium and Ezetimibe in combination are available as tablet dosage forms in the ratio of 1 : 1. A simple, sensitive, accurate and reproducible method have been developed for simultaneous estimation of both the drugs by the Simultaneous equation method, using methanol as solvent....

  • DYSLIPIDEMIA DRUG INDICATIONS.  // Monthly Prescribing Reference;Dec2014, Vol. 30 Issue 12, p25 

    A table is presented which provides information on indications of various drugs for dyslipidemia including colesevelam, ezetimibe, and lomitapide mesylate.

  • FDA rejects new indication for use of combination ezetimibe plus simvastatin in patients with CKD.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p37 

    The article reports on the rejection by the U.S. Food and Drug Administration (FDA) of an indication for use of combination ezetimibe plus simvastatin to prevent major vascular events in patients with chronic kidney disease (CKD).

  • Ezetimibe/simvastatin.  // Reactions Weekly;9/28/2013, Issue 1471, p24 

    The article presents three case studies related to the use of ezetimibe or simvastatin including a 72-year-old man who developed lower extremity myalgia, a 64-year-old patient who developed disabling and leg pain and a 82-year-old woman who developed disabling and back pain.

  • Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding? Paraskevas, Kosmas I.; Veith, Frank J.; Mikhailidis, Dimitri P. // Current Vascular Pharmacology;Jul2011, Vol. 9 Issue 4, p381 

    No abstract available.

  • Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Battaggia, Alessandro; Donzelli, Alberto; Font, Maria; Molteni, Davide; Galvano, Antonio // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics